Retinal Fluid Proteoforms for Therapy Matching: An Emerging Paradigm in Personalized Ophthalmic Care

Abstract

Retinal diseases characterized by exudative fluid accumulation, such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), remain leading causes of vision loss globally. The advent of intravitreal anti-vascular endothelial growth factor (VEGF) therapies has revolutionized treatment; however, response variability highlights the need for precision medicine approaches. Proteoforms—distinct molecular forms of proteins arising from genetic variation, alternative splicing, and post-translational modifications—have emerged as critical biomarkers in retinal fluid. This review synthesizes current evidence on retinal fluid proteoforms, their clinical utility in therapy matching, underlying pathophysiological mechanisms, and future directions for personalized ophthalmic care.

Introduction

Retinal fluid accumulation, manifesting as subretinal, intraretinal, or sub-retinal pigment epithelium (RPE) fluid, is a hallmark of several sight-threatening retinal disorders. Despite significant strides in pharmacotherapy, clinicians encounter considerable heterogeneity in patient responses, underscoring limitations of current one-size-fits-all paradigms. The molecular heterogeneity of retinal fluid, particularly the proteomic landscape, is increasingly recognized as a key determinant of both disease progression and therapeutic response. Proteoforms—unique protein species differing in sequence or modification—offer a novel lens for therapy selection. Harnessing insights from proteomics holds promise for guiding individualized treatment regimens, optimizing outcomes, and reducing the burden of overtreatment.

Epidemiology / Disease Burden

Exudative retinal diseases, notably nAMD and DME, are prevalent among aging populations and individuals with diabetes, respectively. nAMD affects approximately 196 million people worldwide, with projections exceeding 288 million by 2040. DME impacts nearly 21 million diabetic individuals globally. The socioeconomic burden is substantial, encompassing direct healthcare costs, lost productivity, and diminished quality of life. Variability in disease course and response to standard anti-VEGF agents accentuates the need for biomarker-driven stratification to optimize therapeutic efficacy and resource utilization.

Pathophysiology

The accumulation of retinal fluid is a consequence of complex, multifactorial processes involving vascular leakage, impaired fluid clearance, and neuroinflammation. VEGF-driven neovascularization and breakdown of the blood-retinal barrier are central to nAMD and DME. However, recent proteomic analyses reveal that the retinal fluid milieu is highly heterogeneous, containing diverse proteoforms implicated in inflammation (e.g., interleukins, TNF-α), angiogenesis, extracellular matrix remodeling, and oxidative stress. Post-translational modifications such as phosphorylation, glycosylation, and proteolytic cleavage further diversify protein functions, influencing pathogenicity and therapeutic responsiveness.

Risk Factors

Risk factors for exudative retinal diseases include advanced age, diabetes duration and control, hypertension, dyslipidemia, genetic predisposition, and environmental exposures such as smoking. At the molecular level, genetic polymorphisms affecting VEGF, complement pathway proteins, and other modulators of angiogenesis or inflammation can shape the proteoform repertoire of retinal fluid, contributing to inter-individual differences in disease phenotype and progression.

Clinical Features

Patients typically present with painless vision loss, metamorphopsia, and central scotomas. Clinical examination and multimodal imaging (optical coherence tomography [OCT], fluorescein angiography) reveal retinal thickening, cystoid spaces, and subretinal or intraretinal fluid. Notably, the morphological pattern of fluid accumulation—its distribution, extent, and chronicity—can signal underlying molecular mechanisms and predict therapeutic response, further emphasizing the role of proteoform profiling in clinical stratification.

Diagnosis

The diagnosis of exudative retinal diseases relies on a combination of detailed history, fundoscopic examination, and advanced imaging. OCT is the gold standard for detecting and quantifying retinal fluid. Recent advances in mass spectrometry-based proteomics enable the analysis of aqueous or vitreous samples, revealing specific proteoform signatures associated with disease activity, severity, and response to therapy. Integration of proteomic data with imaging and clinical parameters is paving the way for more precise, mechanism-based diagnosis.

Treatment & Management

Current mainstay therapies include intravitreal injections of anti-VEGF agents (ranibizumab, aflibercept, bevacizumab) and, in selected cases, corticosteroids or laser photocoagulation. However, a significant subset of patients exhibits suboptimal or non-durable responses, necessitating frequent injections or therapy switching. Conventional management strategies largely overlook underlying proteomic heterogeneity. Incorporation of proteoform profiling can inform the selection of targeted agents—such as anti-inflammatory or anti-complement therapies—tailored to the predominant pathogenic pathways in individual patients, potentially improving efficacy while minimizing adverse effects.

Recent Advances / Emerging Therapies

Proteomic technologies have advanced rapidly, facilitating high-throughput and sensitive detection of retinal fluid proteoforms. Recent studies have identified distinct proteomic signatures predictive of anti-VEGF responsiveness, steroid sensitivity, or risk of fibrosis. Emerging therapies targeting alternative pathways—complement inhibitors (e.g., pegcetacoplan), integrin antagonists, and angiopoietin/Tie2 modulators—are under clinical investigation, with early evidence suggesting that proteoform-guided therapy matching may enhance response rates and reduce unnecessary exposure to ineffective treatments. Integration of artificial intelligence and machine learning with proteomic data is expected to further refine predictive models for therapy matching.

Guideline Recommendations

While current clinical guidelines emphasize imaging-based assessment to guide treatment decisions, there is growing recognition of the value of molecular biomarkers, including proteoforms, in personalizing care. Professional societies advocate for continued research into fluid biomarkers and their integration into routine clinical workflows. Early adoption of proteomic profiling is recommended in research and specialized centers, with anticipation of broader guideline incorporation as evidence matures and technology becomes more accessible.

Conclusion

The identification and characterization of retinal fluid proteoforms represent a transformative step toward precision medicine in ophthalmology. By enabling therapy matching based on molecular disease signatures, clinicians can optimize treatment selection, improve visual outcomes, and reduce unnecessary interventions. Ongoing research, technological innovation, and multidisciplinary collaboration are essential to realize the full potential of proteoform-guided care. As evidence accumulates, integration of proteomic insights into clinical guidelines is anticipated to reshape the management of exudative retinal diseases and set new standards for personalized ophthalmic care.